SILVER SPRING, Md., Oct. 29, 2013 /PRNewswire/ --
United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the third quarter ended September 30, 2013.
"I am extremely pleased with the results of the third quarter," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "Our medicines are now prescribed for more PAH patients in the United States than any other company."
Total net revenues for the quarter ended September 30, 2013 were $302.2 million, up from $242.5 million for the quarter ended September 30, 2012. Gross margin from sales was $269.3 million for the quarter ended September 30, 2013, compared to $212.9 million for the same quarter last year. Net income for the quarter ended September 30, 2013 was $62.7 million or $1.25 per basic share, compared to $78.1 million or $1.52 per basic share for the same quarter in 2012.
Non-GAAP earnings(1) for the quarter ended September 30, 2013 were $149.3 million, compared to $120.6 million for the same quarter in 2012.
See definition of non-GAAP earnings, a non-GAAP financial measure, and a reconciliation of net income to non-GAAP earnings below.Financial Results for the Three Months Ended September 30, 2013 Revenues
The table below summarizes the components of net revenues (dollars in thousands):Three Months Ended
|SOURCE United Therapeutics Corporation|
Copyright©2012 PR Newswire.
All rights reserved